![Objectives ,[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recomendados
Más contenido relacionado
La actualidad más candente
La actualidad más candente (20)
Destacado
Destacado (9)
Similar a 03.03 management of patients on antiretroviral drugs changi
Similar a 03.03 management of patients on antiretroviral drugs changi (20)
Más de David Ngogoyo
Más de David Ngogoyo (20)
Último
Último (20)
03.03 management of patients on antiretroviral drugs changi
- 1. Module 3 Unit 3: Changing/stopping ART A Rational Approach to a Complicated Subject
- 12. A Rational Approach to the Management of Serious Side Effects Refer to “The National Clinical Manual for ARV Providers”
- 27. 2. Drug Interactions It is not possible to remember all the possible drugs interactions with ARV Drugs Refer to “The National ARV Guidelines”
- 35. 3. Treatment Failure Refer to “The National Clinical Manual for ARV Providers”
Notas del editor
- The extent of inhibition of mitochondrial DNA polymerase gamma is as follows d4T>Zalcitabine (ddC) > Didanosine ( ddI) > Lamivudine (3TC) > Zidovudine (ZDV) > Abacavir (ABC). Generally adverse events are less common in children compared to adults Hyperbilirubinemia, haematuria and nephrolithiasis with Indivanir is more pronounced in children There is high risk of hepatoxicity with ZDV in children below 5 years. Asymptomatic retinal pigmentation with ddI is more likely in children. Be on the look out for diarrhea with NFV and manage the same. The most common adverse events are graded ( see attached table) with suggestions of interventions at each level of grading.
- * In NNRTI containing regimens stopping all 3 drugs at once may allow for development of drug resistance. It is therefore recommended that the NRTI backbone should be continued for 2 weeks if possible to reduce the likelihood of NNRTI resistance developing. See Guidelines to ARV Treatment Minimizing Adverse Events Appropriate drug and regimen selection Dose titration Monitoring and reassuring for effects that are transient Appropriate timing of administration Pharmacological interventions Withdrawal of the offending drug(s)
- Grade 2 rash (maculopapular dry rash over >50%) body surface
- Grade 4 transaminiitis
- Grade 3